Oncimmune Holdings plc: Initiation of a Multi-Centre Trial of EarlyCDT®—Lung in China

Oncimmune Holdings plc (AIM: ONC.L), a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer, and its partner, Genostics Company Limited (“Genostics”), today announce the start of a multi-centre case control study on early lung cancer detection (for screening and nodules) in the People’s Republic of China using an extended panel of autoantibodies to accommodate variations in the biomarkers expressed on cancer cells in Asian populations.

The study will be led by Professor Bai, Professor and Chair of the Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University and will study approximately 1,000 early lung cancers at five leading academic health centres across China. The results are expected in the fourth quarter of 2019 and will be used to support Oncimmune’s application for approval of EarlyCDT—Lung with the China Food and Drug Administration.

Dr Adam M Hill, CEO of Oncimmune commented: “This study is part of our ongoing programme to support the introduction ofEarlyCDT—Lung in China, which is progressing to schedule. We welcome this initiative and the commitment of our partner Genostics in supporting the introduction of EarlyCDT—Lung into what is one of the world’s largest markets.”

Dr Cheung To, Chairman of Gene Group, said: “For more than 20 years, we have been committed to bringing the world’s most cutting-edge technologies and products into China. EarlyCDT—Lung is a unique and innovative product. This China-wide validation study in the Chinese population will help with EarlyCDT—Lung’s future effective commercialisation and accelerate the introduction of an early lung cancer screening program in China, benefiting Chinese patients and families.”

-Ends-

For further information:

Oncimmune Holdings plc

Adam Hill, Chief Executive Officer

contact@oncimmune.co.uk

Zeus Capital Limited (Nominated Adviser and Joint Broker)

Andrew Jones, Mike Seabrook

+44 (0)20 3829 5000

Bryan, Garnier & Co Limited (Joint Broker)

Phil Walker, Dominic Wilson

+44 (0)20 7332 2500

Media enquiries:

Consilium Strategic Communications

Chris Gardner, Matthew Neal, Lindsey Neville

Oncimmune@consilium-comms.com

+44 (0)20 3709 5700

About Oncimmune

Beating cancer, one test at a time

Oncimmune is a leader in the development, manufacture and commercialisation of cancer specific immunodiagnostics for the screening, detection and care of cancer. Oncimmune also develops precision medicine and patient stratification tools for leading pharmaceutical multinationals in both immuno-oncology and autoimmune disease. Oncimmune is working to change how cancer is diagnosed and treated. Its patented technology detects evidence of the body’s natural response to cancer, enabling detection four years or more before standard clinical diagnosis. Oncimmune’s tests facilitate clinical decision-making and are complementary to diagnostic technologies, making them valuable additions to established and new care pathways. Oncimmune partners with leading developers and distributors to make our technology available globally.

Oncimmune was founded in 2002 and launched its platform technology in 2009, followed by its first commercial tests, EarlyCDT—Lung and EarlyCDT—Liver. To date, over 155,000 tests have been performed for patients worldwide and EarlyCDT—Lung is being used in the largest-ever randomised trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) ECLS study of 12,210 high-risk smokers in Scotland. Oncimmune, headquartered at its laboratory facility in Nottingham, UK, has a discovery research centre in Dortmund, Germany and a CLIA lab in Kansas, US as well as offices in London, UK and Shanghai, China. Oncimmune joined the Alternative Investment Market (AIM) of the London Stock Exchange in May 2016 under the ticker ONC.L.

What is EarlyCDT—Lung?

A blood test using a panel of seven immunogenic proteins for the testing of tumour-related antibodies specific to lung cancer.

For more information, visit www.oncimmune.com